Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

regarding returning cash to shareholders were also vague and reflected Elan's lack of focus on enhancing shareholder value. In general, Royalty Pharma believes that Elan expressed little concern for the views of Elan Shareholders during the Tysabri Conference Call, which included the following statements[12]:

  • "But to emphasize, the US$3.25 billion is a lot of money. There is a lot of assets out there. Our goal as we sit here today is that the majority of that capital over time should be put into businesses, again, in a balanced way. But again, some portion of it, given that we brought forward the value, will be returned to shareholders at the right time and post-close and as we sequence it against other transactions."
  • "As far as usage of this capital upon close, they include, but are not limited to, therapeutic opportunities across broad therapies.  We are basically agnostic to therapeutic focus."
  • "we are somewhat agnostic to different geographies . . . they all hold some appeal, depending on what part of the geography you're interested in . . .  we are not particularly interested in large markets, large indications of primary care, but large markets in smaller indications would be attractive and vice versa."
  • "And we still do like some very specific, unique science things."
  • "At the right time and in the right manner, we would intend to provide some portion of this capital back to shareholders over time."
  • "we are not going to satisfy all investors on every category . . . So anyway, everyone can vote with their feet."
  • The Elan Stock price fell by approximately 10 percent on the day of the Tysabri Conference Call.

    Elan's announcements since its receipt of Royalty Pharma's Proposal

    Royalty Pharma believes that Elan has changed its messages since receiving Royalty Pharma's Proposal, particularly with regard to shareholder returns.

    Having previously said that sharehol
    '/>"/>

    SOURCE RP Management, LLC
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
    2. Cowen Healthcare Royalty Partners Raises $1 Billion
    3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
    4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
    5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
    6. AVANIR Pharmaceuticals To participate in two conferences in March
    7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
    8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
    9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
    10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
    11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/13/2014)... (PRWEB) July 13, 2014 2014 Deep ... is a professional and in-depth study on the current ... China. , The report provides a basic overview of ... Global market analysis and Chinese domestic market analysis are ... competitive landscape of the market. A comparison between the ...
    (Date:7/12/2014)... July 12, 2014 This ... reagents used in the life science industry. ... life science reagents market towards remarkable growth. ... and providers of life science reagents. , ... http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global life ...
    (Date:7/11/2014)... 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
    (Date:7/11/2014)... , Not for release, publication or ... any jurisdiction where to do so would constitute a violation ... plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... it has held a meeting with representatives of AbbVie. ... prior agreement or approval of AbbVie. A further ...
    Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2
    ... Minds, Establishes New Company to Commercialize ... Novel Technology from UC ... investment,firm specializing in early stage university business ventures, has,established RF ... technology invented at UC Davis., The newly formed RF ...
    ... TAIAN CITY, Shandong, China, June 30 /Xinhua-PRNewswire-FirstCall/ --,China ... or "the,Company"), one of the leading plasma-based pharmaceutical ... announced that the Company,received the approval from the ... new plasma collection station in Pu Bei County, ...
    ... Cellumen, Inc., the Cellular,Systems Biology Company, announced today ... Center for Toxicology Research (NCTR), a,research center of ... Cellumen will use its proprietary CellCiphr(R) toxicity risk,assessment ... toxicity,compounds including both failed and marketed drugs for ...
    Cached Biology Technology:Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis 2China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province 2China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province 3Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology 2
    (Date:7/11/2014)... Wildlife Conservation Society shows that no-take zones in ... such as lobster, conch, and fish recover from ... areas. , The reporttitled "Review of the Benefits ... literature from no-take areas around the world. The ... recognized expert in marine protected areas and fisheries ...
    (Date:7/11/2014)... July 11, 2014--Researchers at the Department of Energy,s ... 100 awards, presented by R&D Magazine in recognition ... "These awards recognize the tremendous value of our ... "Research and development at the National Labs continues ... and pursue the scientific and technological innovations necessary ...
    (Date:7/11/2014)... South Wales, Australia when NASA,s Aqua satellite passed overhead ... 11 (12:35 p.m. local time/11:35 p.m. EDT on July ... (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard captured ... smoke (light brown) from various fires. Actively burning areas, ... , The New South Wales, Australia Government website "NSW ...
    Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
    ... Health has named researchers at Baylor College of Medicine ... and only recipients of the inaugural Quantum Grant for ... and blood vessels for the treatment of stroke. , ... Institute of Biomedical Imaging and Bioengineering (NIBIB), part of ...
    ... two candidate vaccines that may eventually be used together ... are published in the December 15 issue of The ... S. Graham, MD, PhD, and colleagues from the National ... the Fred Hutchinson Cancer Research Center in Seattle, and ...
    ... heart muscle ?even though it was grown in the ... the goal of creating replacement parts for damaged human ... just a spoonful of loose heart cells. , This ... in growing bioengineered heart muscle, or BEHM, with organized ...
    Cached Biology News:First Quantum Grant to fund stem cell repair of damage from stroke 2Progress made in HIV vaccine development 2A new approach to growing heart muscle 2A new approach to growing heart muscle 3A new approach to growing heart muscle 4
    3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
    Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
    ... Rat adult normal paraffin tissue ... genes or proteins of interest in ... tissues. Rat brain, heart, kidney, ... tissues are arrayed on positively charged ...
    GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
    Biology Products: